Association of clonal hematopoiesis and AITL: genetic evidence for stem cell origin, etiology and prediction of secondary hematologic malignancy in AITL

Shuhua Cheng[1], Wei Zheng[2], Giorgio Inghirami[1], Wayne Tam[1]*
[1]Department of Pathology and Laboratory Medicine, [2] Genomics Resources Core Facility, Weill Cornell Medicine, New York, NY 10021

Supplemental Text

Fig.1A: 6 illustrative cases in which common mutated HSC developed into CH and AITL or PTCL-NOS

In Patient #1, identical *TET2* and *DNMT3A* somatic mutations, p. E1089fs and p.F791L, were identified both in CH (VAFs: 48.39%, 34.62%) and in the neoplastic T cells in the diagnostic LN specimen (VAFs: 36.87%, 27.59%) (**Figure 1A**). The other four pathogenic variants, *TET2* p.Q743*, *RHOA* p.G17V, *IDH2* p.R172T and *PTPRF* p.R654H, were detected at high VAFs in the LN but at much lower VAFs in the BM (**Figure 1A**). These results demonstrate that the latter four mutations are likely acquired at a later time point during AITL development (late mutations) and the low-VAF variants detected in the BM represent minimal involvement in the BM and not CH. Patient #4 had no overt evidence of a myeloid neoplasm in the BM while diagnosed with AITL, and had 2.1% bone marrow involvement by AITL according to immunophenotypic and gene rearrangement studies. The T cell NGS panel identified 7 pathogenic mutations in the primary lymphoma, of which 6 were also found in the matched BM. The allelic burden of the two mutations with the highest VAFs (*DNMT3A* p. Q678*, VAF=6.22%; *ATP1A3* p.V216M, VAF=4.47%), were 2 to 3 times that of the estimated tumor burden (2.1%) in the BM, suggesting that *DNMT3A* p. Q678* and *ATP1A3* p.V216M were not only present in the neoplastic T-cells but also associated with CH. The other 5 mutations, including *RHOA* p.G17V and *IDH2* p. R172G, were found at the VAFs ranging from 0% to 1.5% in the BM, consistent with lymphoma involvement rather than CH. These results suggest that these 5 mutations were acquired subsequent to the CH-associated mutations described above. Interestingly, sequencing a relapsed lymphoma specimen from this case identified only one mutation *DNMT3A* p. Q678*. This mutation information in the relapsed lymphoma helps clarify the clonal architecture of both the primary AITL and CH. First, it suggests that the primary AITL harbored two clones, a dominant clone with *ATP1A3*, *DLGAP3*, *TET2*, *RHOA* and *IDH2* mutations, and a minor clone with *DNMT3A* mutation, the latter being the precursor clone for relapse. Second, it also implies that there are 2 clones in CH, one associated with the *DNMT3A* mutation and the other with the *ATP1A3* mutation. In Patient #10, the CH-associated variant shared between the primary lymphoma and the matched BM, *TET2* p. N1484K, was identified at high allelic burden in both the lymphoma and BM samples (VAFs in LN vs BM, 47.33% vs 38.26%,). Another *TET2* mutation, p. D1378G, was also identified in the both the LN and the BM, at VAFs of 16.89% and 0.32% respectively. The large difference of the VAF in the BM of the two *TET2* mutations suggests that they may belong to different HSC clones, each of which has markedly different CH contribution, or the *TET2* p.D1378G mutation was acquired subsequent to the *TET2* p.N1484K mutation as a subclonal mutation in the HSC. The other 3 mutations: *TET2* p.V415fs, *RHOA* p.G17V and *IDH2* p.R172T were present exclusively in the lymphoma sample. In patient #29, the *DNMT3A* R882H hot-spot mutation was shared at high VAFs in both the lymphoma and BM (46% and 35.6%), consistent with a CH-associated mutation, while the other 4 mutations detected in the LN was present in the BM at low VAFs, consistent with BM involvement by T-cell lymphoma. Interestingly, both the *TET2* N1484K mutation in patient #10 and the *DNMT3A* R882H mutation in patient #29 were present in the primary lymphomas at a VAF of close to 50%, about 3-4 times the allelic fractions of other mutations identified in the LN. This finding implies the presence of these mutations in almost the entire cell population in the LN. However, based on immuno-morphologic evaluation and the VAF of the other mutations identified in the LN, the tumor burden in the LN for these two cases is about 20-40%. This raises the possibility that besides the neoplastic T cells, reactive lymphocytes in these two cases might also harbor the CH-associated mutations.

In the two PTCL-NOS cases (#2 and #18), we observed similar findings as described above for AITL (**Fig. 1A**). Patient #2 showed eosinophilia with 1.5% neoplastic T cells involvement in the BM. Two pathogenic *STAT3* mutations were identified. One could be considered a CH-associated mutation (*STAT3* p.Y657_K658insALL, VAFs in LN vs BM, 21.61% vs 8.34%) since its VAF is considerably higher than the estimated percentage of tumor involvement in the BM. The other is most likely PTCL-NOS-related mutation (*STAT3* p.W474*). This *STAT3* nonsense mutation had the allelic burden of 18.33% in the primary lymphoma but was present at much lower level (VAF = 2%) in the matched PB, in line with the estimated tumor burden. Patient #18 presented mildly hypercellular marrow with mild granulocytic hyperplasia while diagnosed with PTCL-NOS and had no involvement in the BM per the overall pathologic studies. The NGS target panel identified a splice mutation in *TET2* (c.3501-1G>A) and a missense mutation in *SETX* (p. Y2258D) shared between CH and PTCL-NOS. Two mutations (*TP53* p.P151T and *ARID1A* p. G779*) were only found in the neoplastic T cells, presumably representing later mutations in PTCL-NOS development following acquisition of the *TET2* and *SETX* mutations.

Fig. 3: three AITL cases with concurrent hematologic neoplasm

Patient #5 was initially diagnosed as AITL, followed by a diagnosis of chronic myelomonocytic leukemia (CMML) 7 months later. In the BM specimen, taken four months prior to the diagnosis of CMML and sequenced in this study, the overall pathologic findings showed 1-5% involvement by AITL and suspected involvement by a myeloid neoplasm. Three identical mutations, including 2 *TET2* and one *DNMT3A* mutations: p.I274delinsISfs, p.L1830* and p.W893S alterations, respectively, were identified in both the LN and BM with high allele burdens (VAF range, 25-50%, **Fig. 3A**, **Suppl. Table 3**). In addition, pathogenic *SRSF2* and *JAK2* mutations were identified in the BM. These findings support a scenario in which AITL and CMML arose via divergent evolution from a common HSC clone mutated in the CH-associated *TET2* and *DNMT3A* genes. Subsequent development involves accumulation of additional mutations: *SRSF2* and *JAK2* mutations from CH to CMML, and *IDH2* with other mutations to AITL.

Patient #20 was initially diagnosed with PV and progressed to post-PV PMF after 10 years. Two months later, the patient was also diagnosed with AITL. We sequenced the T-cell lymphoma in the LN and the paired bone marrow specimen with post-PV PMF (the initial PV specimen was unavailable). The overall pathologic studies showed no lymphoma involvement in the BM. The NGS sequencing revealed that the T and myeloid malignant cells harbored two identical destructive *TET2* mutations with high mutant allele burdens, p. Q939* (20% VAF) and p. E1026delinsXDfs (42% VAF). The driver mutation for MPN, *JAK2* p.V617F, was not only present in the post-PV PMF (88% VAF), but also found in the concomitant AITL with the mutant allele burden of 54.5% (**Fig. 3B, Suppl. Table 3**). No *IDH2* or *RHOA* mutation was detected in the AITL. These findings suggest that the *JAK2* driver mutation was acquired early in the HSC. Indeed, *JAK2* mutation was thought to be an early event in PV [1]. In this particular case, the combination of *TET2* and *JAK2* V617F may also be sufficient to drive AITL development, as no other drivers like *IDH2* or *RHOA* were found.

Patient #14 initially presented as immune thrombocytopenia (ITP) and had a splenectomy in 2008. He was diagnosed with AITL two years later and DLBCL about 7 years later. We sequenced two diagnostic tissue samples for the AITL and DLBCL, respectively, as well as one BM sample collected from this patient in 2010. The morphologic, immunophenotyping and molecular findings confirmed that the BM sample was not involved by AITL or a myeloid neoplasm. Interestingly, two nonsense *TET2* mutations, p.K454* and p.K1799*, were identified in all three samples with the VAFs ranging from 32% to 51%. An additional pathologic mutation *EZH2*, p. Y646S, was detected only in the DLBCL (**Fig. 3C, Suppl. Table 3)**. The results from this patient suggest that the mutated HSC clone, harboring *TET2* p.K454* and p.K1799* alterations, differentiates into progeny cells of three different lineages (myeloid, T lymphoid, B lymphoid), each of which gives rise to CH, or transformed to AITL or DLBCL. The additional *EZH2* mutation has been reported in B-cell lymphomas[2,3] and likely plays a role in the DLBCL development.

Method

Patients and Study Samples

All tissue samples (27 lymph node tissue specimens, 27 bone marrow aspirate/peripheral blood samples) were collected from 25 AITL or 2 PTCL NOS patients who were diagnosed or confirmed from June 2010 to December 2019 following World Health Organization classification criteria by attending hematopathologists at NYP/Weill Cornell Medical Center, and clinical Information was obtained from electronic clinical records. Of these 27 study cases, 4 were initially diagnosed with PTCL with THF phenotype (**Suppl. Table. 1**), and included as the part of the AITL cases according to their similar clinical and molecular features as recently proposed by WHO[4]. This study was conducted in accordance with the Declaration of Helsinki regulations of the protocols approved by the Institutional Review Board of Weill Cornell Medicine, New York, USA. Written consent for use of the samples for research was obtained from patients or their guardians.

Genomic DNA was extracted from lymph node tissue and bone marrow or PBMC cell pellets following manufacturer's instructions (QIAamp DNA Mini Kit, Qiagen, Germantown). DNA samples and sequencing libraries used in targeting sequencing as described below were quantitated by Tape Station (Agilent Technologies, Santa Clara) and Qubit (Thermo Fisher Scientific, Singapore).

T Cell Targeted Sequencing

A 538 gene targeted sequencing panel were designed to investigate the genomic profile of the primary tumors and the BM/PB tissues[5]. The genomic regions covered by sequencing include coding exons and splice sites of these genes (target region: ~3.2 Mb) that were reported being recurrently mutated (>2) in mature T-cell neoplasms, as well as genomic regions corresponding to recurrent translocations. Using an input of genomic DNA of at least 100 ng isolated from frozen tissues or FFPE samples, the next-generation sequencing (NGS) libraries were constructed using

the KAPA Hyperplus Kit (Roche, Basel, Switzerland), and hybrid selection was performed with the Twist Library Prep Kit (Twist Biosciences, San Francisco, CA, USA), according to the manufacturer's protocols. Multiplexed libraries were sequenced using 150-bp paired end Hiseq4000 sequencers (Illumina, San Diego, CA, USA). NEXTGENe software (Softgenetics, State College, PA, USA) was used to perform bioinformatic analysis (SNV and INDEL variant calls) with standard settings recommended by the manufacturer. Specifically, cutoff values for the variant allele frequency, population frequencies, and strand bias were set at 5%, 0.01%, and 1:5, respectively.

Myeloid NGS Panel

Targeted enrichment of 45 genes recurrently mutated in myeloid malignancies was performed using the Thunderstorm system with a customized primer panel[6]. The primers target coding exons of the genes, leading to a total of 726 amplicons. Libraries were prepared by microdroplet-based PCR target enrichment method from DNA, followed by sequencing using the Illumina MiSeq yielding 260-bp paired end reads. Sequencing data were analyzed and reported with a customized analytical pipeline. This NGS panel testing is performed in a clinical lab CLIA-certified and accredited by the College of American Pathologists.

Data Analysis

Data analysis were conducted with GraphPad/Prism 5 software and various R packages, including base packages, ggplot2, ComplexHeatmap and Maftools. The survival comparison was analyzed using Kaplan-Meier curves (log-rank test, significance defined as $p < 0.05$).

Supplemental figure legend

Suppl. Fig. 1. AITL variants involving BM/PB. (A**)** Venn diagram illustrates the distribution of the shared, and the LN or BM/PB-specific mutations. Note that the variants detected in the BM/PB due to lymphoma involvement are included in this diagram, in contrast to Fig. 1B presented in the main text. (B) The type of variants and mutation frequencies (relative to the total number of cases) for the top 6 mutated genes identified in AITL/PTCL-NOS and matched BM/PB are shown. Different colors represent variant classifications as indicated. (C) Heat map showing the mutations detected in the BM/PB samples in each case. Only the major recurrent mutations are listed. The tumor burden (TB) in the BM/PB was estimated based on morphologic and immunophenotypic and molecular assessment, and the predicted CH status (determined based on comparison of the VAF of the mutations with TB) is indicated. Blue rectangles highlight the VAFs of the variants due to AITL involvement. CH, clonal hematopoiesis; +, presence of CH; -, absence of CH; $, mutation in *STAT3*; ^, mutation in *DDX11*. (D) Dot plot comparing VAFs of the CH-associated variants and those related to lymphoma involvement in the BM/PB specimens. Mean ±SEM of the VAFs is shown for each subgroup. (E) The proportion of the cases with or without BM or PB involvement by the neoplastic T cells (IVS), or with/without clonal hematopoiesis (CH), respectively, is summarized.

Suppl. Fig.2 Overall and lymphoma-specific genomic alterations in primary AITL/PTCL-NOS. (A) Mutation plot showing the overall mutation profile in the LN tissues involved by AITL./PTCL-NOS. **(**B**)** Mutation plot showing the AITL/PTCL-NOS-specific mutations identified in lymphoma samples after excluding the CH-associated variants. Top bars on each plot indicate the numbers of variants detected per sample. The percentage at right shows the gene mutation frequency in the cohort of the patients. Sample IDs are indicated at the bottom of each plot. Variant classifications are indicated with different colors.

Suppl. Fig.3 Overall and CH-related genomic alterations in the matched BM/PB samples. (A**)** The overall mutation profile in the BM/PB shown. (B) The CH–related mutation profile identified in the BM/PB is shown after excluding the variants due to AITL involvement. Top bars on each plot indicate the numbers of the variants detected per sample. The percentage showing gene mutation frequency in the patient cohort is shown at the right. Sample IDs are indicated at the bottom of each plot. Variant classifications are indicated with different colors.

Suppl. Fig. 4 Comparison of VAFs of the variants found in paired AITL and BM/PB samples. Red color highlights the CH-associated variants shared between the LN and BM/PB compartments. The black circles indicate variants specific to the lymphomas, the pink circles represent mutations specific to BM/PB. Cases that were not presented in Fig. 1 and Fig. 3 are shown in this figure. In Pt #7, three mutations specific to BM were found in PLCG1, ACSL3 and CTTNBP2. These may represent novel CH-associated mutations. In Pt #8, DNMT3A p.W330*, likely

representing a minor CH clone, was also found specifically in the BM. In Pt.#24, an additional ASXL1 frameshift mutation was identified in the BM, which showed hypercellularity with increased granulopoiesis. In this patient, we appeared to capture the acquisition of a subclonal *JAK2* V617F mutation during tumor progression, which was identified by the myeloid panel in the purified granulocytes from the PB but not detected in the BM one year before (#24).

Suppl. Fig. 5. Summary of all CH-associated and non-CH-associated mutations identified in AITL/PTCL, NOS and their matched BM/PB. Pt#, Patient ID.

Reference

1. Bellanne-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. *Blood*. 2006;108(1):346-352.
2. Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. *Cancer Cell*. 2013;23(5):677-692.
3. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet*. 2010;42(2):181-185.
4. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127(20):2375-2390.
5. Fiore D, Cappelli LV, Zumbo P, et al. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. *Cancers (Basel)*. 2020;12(6).
6. Cheng S, Singh K, Liu YC, Kluk MJ, Hassane DC, Tam W. Targeted sequencing of recurrently mutated genes in myeloid neoplasms using the Raindance Thunderstorm-Illumina Miseq Platform: My Heme (Myeloid Hematologic Malignancy) Panel. the Association for Molecular Pathology (AMP) 2017 Annual Meeting. Vol. 19: The Journal of Molecular Diagnostics; 2017:962.

Suppl. Fig. 1


A
AITL
PTCL-NOS
BM/PB
Shared
variants
30
78
9
LN-
specific
variants
Variants
specific to
BM/PB
B
AITL/PTCL-NOS
(N=28)
Paired BM or PB
(N=26)
75%
TET2
76%
50%
RHOA
36%
25%
DNMT3A
24%
25%
IDH2
12%
11%
TTN
8%
7%
PLCG1
12%
Frame_Shift_Del
Frame_Shift_Ins
Missense_Mutation
Multi_Hit
Nonsense_Mutation
Splice_Site
60%
40%
20%
0%
0%
20%
40%
60%
Percent of Cases
C
BM/PB
RHOA
IDH2
DNMA3A
TET2_1
TET2_1
TB
CH
52%
0%
Patient ID
#1 0.43 0 34.62 48.39 0 0.5% +
#2 0 0 0 0 0 1.5% +
#3 0 0 0 20.26 16.03 0.0% +
#4 0.68 1.27 6.22 0.82 0 2.1% +
#5 0 0.23 48.19 42.79 34.32 1-5% +
#6 0 0 0 0.39 0 0.0% +
#7 0.12 0 0 0 0 4.0% -
#8 0 0 45 43.37 2.61 0.1% +
#9 0.24 0 0 0 0 1-5% -
#10 0 0 0 39.26 0.32 0.0% +
#11 0 0 0 0 0 0.0% -
#12 0 0 0 1.25 2.29 1-5% -
#14 0 0 0 32.71 51.49 0.0% +
#15 0 0 0 44.65 0 1-5% +
#16 5.21 0 10.85 0 0 10.0% +
#17 0.44 0 0 0.24 0.66 0.4% -
#18 0 0 0 3 0 0.0% +
#19 0 0 0 0 0 1-5% +
#20 0 0 0 42.29 39.37 0.0% +
#21 0 0 0 0 0 0.0% -
#22 0.82 0 0 2.25 0 <1% +
#23 4 4 0 5.64 0 10.0% -
#24 0 0 0 41.07 43.65 0.0% +
#25 0 0 0.24 23.08 0 0.0% +
#26 0 0 0 0 0 2.1% -
#28 0 0 0 5.47 10.89 2.4% +
#29 0.1 0 35.6 0.56 0 1-5% +
D
BM/PB
P < 0.0001
VAF (%)
75
50
50
40
30
20
10
2
1
0
CH
Variants
(n=37)
Tumor variants
by involvement
(n =44)
E
Pos
Neg
100%
80%
60%
40%
20%
0%
% Cases
IVS
CH

Suppl. Fig.2

A

Overall genomic alterations (LN, n =28)



Filtering out the variants associated with CH

B

AITL/PTCL-NOS-specific genomic alterations (LN, n=21)



Suppl. Fig.3

A

Overall genomic alterations (paired BM/PB, n =25)



Filtering out the variants by lymphoma involvement

B

CH-associated genomic alterations (Paired BM/PB, n =19)



Frame_Shift_Del
Frame_Shift_Ins
Missense_Mutation
Splice_Site
Nonsense_Mutation
In_Frame_Del
In_Frame_Ins
Multi_Hit

Suppl. Fig. 4 Comparison of VAFs of the variants found in paired AITL and BM/PB samples for each patient (Continued)













Suppl. Fig. 4 Comparing VAFs of the variants found in paired AITL and BM/PB samples for each patient (Continued)













Suppl. Fig. 4 Comparing VAFs of the variants found in paired AITL and BM/PB samples for each patient













Suppl. Fig. 5. Summary of individual mutations shared and unique in neoplastic T cells and untransformed myeloid tissues



Supplemental Table 1 Patient characteristic

No.	Patient ID	Type of Specimens	Sex	Age	Dx	Pathology of BM/PBL	Concurrent hematologic Malignancy	Morphology	MFC	TCRG Rearrangement	TB
1	#1	BM	F	58	Lung cancer, AITL	megakaryocytes slightly increased in number without significant cytologic atypia. PBL, Normocytic anemia. Leukocytosis with neutrophilia	No	+	0.5%	n/a	0.5%
2	#2	PBL	M	33	PTCL, NOS	BM, hypocellular bone marrow with relative eosinophilia, PBL, eosinophilia	No	-	1.50%	PCR+	1.5%
3	#3	PBL	M	51	AITL	unremarkable	No	-	0	PCR-	0.0%
4	#4	BM	F	65	AITL	involvement, megakaryocytes are focally clustered and some have atypical nuclear lobation, PBL, unremarkable	No	+	2.10%	PCR+	2.1%
5	#5	BM	F	65	AITL	granulopoiesis, dysgranulopoiesis, decreased erythropoiesis, monocytosis, unremarkable T cells. PBL, Absolute monocytosis.	CMML, 10 months post-AITL Dx	-	0	PCR+	1-5%[$]
6	#6	PBL	M	75	AITL	Megakaryocytes were dysplastic (>10%). Including small / giant forms with hypo / hyperlobulated nuclei. Myelopoiesis is hyperplastic and slightly left-shifted. Mild dysgranulopoiesis is present (<10%) with giant forms and abnormal segmentation.	No	-	0	n/a	0.0%
7	#7	BM	M	70	AITL	involvement	No	+	4%	n/a	4.0%
8	#8	BM	M	72	Prostate cancer, PTCL-TFH	involvement	No	+	0.10%	n/a	0.1%
9	#9	BM	F	53	AITL	unremarkable	No	-	0	PCR+	1-5%[$]
10	#10	BM	M	63	AITL	unremarkable	No	-	0	PCR-	0.0%
11	#11	BM	F	70	AITL	ITP	No	-	0	PCR-	0.0%
12	#12	PBL	M	75	AITL	unremarkable	No	-	0	PCR+	1-5%
13	#14	BM	M	77	PTCL-TFH, DLBCL	ITP	DLBCL, 7 years post-AITL Dx	-	0	PCR-	0.0%
14	#15	BM	M	76	AITL	unremarkable	No	-	0	PCR+	1-5%[$]
15	#16	BM	F	84	AITL	involvement	No	+	10%	PCR+	10.0%
16	#17	PBL	M	80	AITL		No	-	0.40%	PCR+	0.4%
17	#18	BM	M	63	PTCL, NOS	Mildly hypercellular marrow with mild granulocytic hyperplasia	No	-	0	PCR-	0.0%
18	#19	BM	F	53	AITL	unremarkable	No	-	0	PCR+	1-5%[$]
19	#20	BM	M	45	Lung Cancer, post-PV MF, PTCL-TFH	post-PV myelofibrosis	PV, post-PV myelofibrosis prior to AITL Dx	-	0	PCR-	0.0%
20	#21	BM	F	42	AITL	unremarkable	No	-	0	PCR-	0.0%
21	#22	BM	F	63	AITL	a mildly hypercellular bone marrow with myeloid hyperplasia	No	-	0	PCR-	<1%
22	#23	BM	M	65	DLBCL and AITL	unremarkable	DLBCL	+	10%	PCR+	10.0%
23	#24	BM	M	38	AITL	Myelopoiesis is hyperplastic and slightly left-shifted with ~4% blasts. Evidence of significant dysplasia is not seen	No	-	0	PCR-	0.0%
24	#25	BM	M	70	AITL	Hypercellular bone marrow with myeloid hyperplasia	No	-	0	PCR-	0.0%
25	#26	BM	M	63	PTCL-TFH	involvement	No	+	2.10%	PCR+	2.1%
26	#27	no matched BM or PBL	F	67	Lung cancer, PTCL, NOS	n/a	n/a	n/a	n/a	n/a	n/a
27	#28	BM	F	79	AITL	involvement	No	+	2.40%	PCR+	2.4%
28	#29	BM	M	58	CTCL to AITL	small population of abnormal myeloid blasts noted in BM, but no MPN diagnosized	No	-	0	PCR+	1-5%[$]

Pt#, Patient ID, T, type of specimen, HP, histopathology
IM, immunophenotyping, MP, molecular pathology testing
TB, neoplastic T cell burden by BM involvement
CH, clonal hematopoisis
IC, suspicious but inconclusive
$ limit of detection of TCRG (1-5%)
n/a, data unavailable
DLBCL, diffuse large B cell lymphoma
CMML, Chronic Myelomonocytic Leukemia
PCR+, monoclonal TCR rearrangement
AITL, angioimmunoblastic T-cell lymphoma
PTCL, peripheral T-cell lymphoma
CTCL, cutaneous T-cell lymphoma
MF, myelofibrosis
MCF, multiple color flow cytometry

Supplemental Table 2 Variant summary

		Primary AITL lymphoma				Paired BM/PBL[$]			
		summary	**Mean**	**Median**	**Percent**	**summary**	**Mean**	**Median**	**Percent**
Variant Classification	Frame_Shift_Del	9	0.333	0	8.82	6	0.316	0	13.64
	Frame_Shift_Ins	7	0.259	0	6.86	7	0.316	0	15.91
	In_Frame_Del	1	0.037	0	0.98	0	0	0	0.00
	In_Frame_Ins	1	0.037	0	0.98	1	0.053	0	2.27
	Missense_Mutation	62	2.296	1	60.78	17	0.789	1	38.64
	Nonsense_Mutation	20	0.741	1	19.61	12	0.579	0	27.27
	Splice_Site	2	0.074	0	1.96	1	0.053	0	2.27
Total		102	3.778	3	100.00	44	2.105	2	100.00
No. of Samples		27				27*			
No. of Mutated genes		37				14			

*A total of 23 bone marrow and 4 PBL samples were sequenced. Among 27 BM/PB samples, 20 had identifiable mutated genes after filtering out the variants involved.

[$] the variants from the invovled lymphoma excluded

Supplemental Table3 Individival mutations and their VAFs in the lymphoma cases and matched BM/PB

No. of Patient	Patient ID	Dx	Mutations	Alt% in lymphoma (LN)	Alt% in BM or PBL	Purified granulocytes from PB of AITL patients	Note
1	Patient 1#	Lung cancer, AITL	TET2 p.E1089fs	36.87	48.39		
			DNMT3A p.F701L	27.59	34.62		
			TET2 p.Q743*	16.69	0.43		
			IDH2 p.R172T	20.47	0.00		
			RHOA p.G17V	14.17	0.43		
2	Patient 2#	PTCL, NOS	STAT3 p.Y657_K658insALL	21.61	8.34		
			STAT3 p.W474*	18.33	2		
3	Patient 3#	AITL	TET2 p.P1367R	27.04	20.26		
			TET2 p.Y1337*	24.97	16.03		
4	Patient 4#	AITL	ATP1A3 p.V216M	11.38	4.47		
			IDH2 p.R172G	8.81	1.27		
			TET2 p.S1612Lfs	7.34	0		
			DLGAP3 p.G85Vfs	6.27	1.52		
			RHOA p.G17V	5.53	0.68		
			TET2 p.R1167K	5.11	0.82		
			DNMT3A p.Q678*	1.95	6.22		
5	Patient 5#	AITL	CD28 p.T195P	7.32	0.00		
			CDHR4 p.V647L	10.15	0.28		
			DNMT3A p.W893S	36.08	48.19		
			IDH2 p.R172S	7.08	0.23		
			JAK2 p.V617F	0.00	3.00		
			SRSF2	0.00	28.00		
			NRG1 p.P174L	8.70	0.00		
			RHOA p.G17V	7.79	0.00		
			TET2 p.I274delinsISfs	32.13	42.79		
			TET2 p.L1830*	25.66	34.32		
6	Patient 6#	AITL	TET2 p.Y1679delinsYTfs	12.6	0.39		
			RHOA p.G17V	6.28	0.00		
7	Patient 7#	AITL	CHSY3 p.R375W	13.06	0		
			CREB3L1 p.P187T	20.21	0.34		
			CSMD3 p.H1786N	14.13	0.46		
			CTNNB1 p.T41A	20.86	0.75		
			GNAI2 p.G45R	25.62	0.34		
			GRID2 p.N52Y	13.51	0.57		
			LAMA2 p.G2202S	18.97	0.74		
			MAPK3 p.D338E	39.61	0.743034056		
			PCDH17 p.V1117A	19.96	0.239616613		
			PLCG1 p.S345F	0	0.175284838		
			POT1 p.T105K	18.3	1.080351114		
			RHOA p.G17A	20.48	0.116009281		
			SYNE1 p.M5804T	19.46	0.347912525		
			TTN p.E28924A	18.11	0.636942675		
			TTN p.P12842T	11.4	0.401854714		
			VAV1 p.R798Q	19.81	0.421545667		
			ZZEF1 p.D1205V	23.15	0.443951165		
			ACSL3 p.Q419Lfs	0	8.66		
			CTTNBP2 p.N442N	0	13.66204417		
8	Patient 8#	Prostate cancer PTCL-TFH	TET2 p.S315fs	32.17	43.37349398		
			TET2 c.3594+1G>A	14.64	2.605459057		
			DNMT3A p.Arg771Gln	36	45		
			DNMT3A p.Trp330*	0	1.66		
9	Patient 9#	AITL	TET2 p.Q622*	15.65	0		
			RHOA p.G17V	15.04	0.241400121		
			DOCK7 p.P240S	11.19	0		
10	Patient 10#	AITL	TET2 p.D1376G	16.89	0.31512605		
			TET2 p.V415fs	16.62	0		
			RHOA p.G17V	10.92	0		
			IDH2 p.R172T	10.02	0		
			TET2 p.N1484K	47.33	38.26		
11	Patient 11#	AITL	RHOA p.G17V	6.36	0		
			DNAH5 p.V2636L	8.12	0		
			IDH2 p.R172K	7.75	0		
12	Patient 12#	AITL	RUNX1T1 p.V286A	10.49	1.11		
			TET2 p.Q626*	11.17	1.25		
			TET2 p.N1346del	12.4	2.29		
			VAV1 p.G611R	18.45	2.09		

13	Patient 14#	PTCL-TFH DLBCL	TET2 p.K454* TET2 p.K1799* EZH2 p.Y646S	34.50 35.94 0.00	32.71 51.49 0.00		41.8[&] 33.6[&] 29.9[&]
14	Patient 15#	AITL	TET2 p.Q705* PHF6 p.K132fs	28.68 2.56	44.65 16.94		
15	Patient 16#	AITL	DNMT3A p.G413fs RHOA p.G17V	5.30 6.68	10.85 5.21		
16	Patient #17	AITL	RHOA p.G17V TET2 p.Q1274* TET2 p.Y1589*	21.2 20.44 24.14	0.44 0.24 0.66		
17	Patient #18	PTCL, NOS	ARID1A p.G779* SETX p.Y2258D TET2 c.3501-1G>A TP53 p.P151T	14.08 41.47 30.3 47.38	0 2 3 0		
18	Patient #19	AITL	DDX11 p.L659Cfs	6.24	8.39		
19	Patient #20	Lung Cancer post-PV MF PTCL-TFH	TET2 p.Q939* TET2 p.E1026delinsXDfs JAK2 p.V617F	36.59 19.64 54.48	42.29 39.37 88		
20	Patient #21	AITL	BCOR p.W191*	5.1	0		
21	Patient #22	AITL	RHOA p.G17V TET2 p.Q574* TP53 p.G244D PLCG1 p.R748S	17.99 25.85 7.83 11.51	0.82 2.25 0.52 0.33		
22	Patient #23	DLBCL AITL	IDH2 p.R172K RHOA p.G17V TET2 p.K1299delinsXVfs	9.17 11.17 23.69	4 4 5.64		
23	Patient #24	AITL	TET2 p.G1861V TTN p.W25027* TET2 p.S1607* JAK2 p.V617F ASXL1 p.G646Wfs*12	13.9 12.17 11.12 0 0	41.07 43 43.65 0 36	39.3 n/a 32.6 8.7 28.6	
24	Patient #25	Prostate cancer HL AITL	DNMT3A p.L500Sfs RHOA p.G17V TET2 p.Y1255Dfs	6.29 5.5 21.44	0.24 0 23.08		
25	Patient #26	PTCL-TFH	PIK3R1 p.K567KE	15.61	1.33		
26	Patient #27	PTCL, NOS Lung cancer	LRP1B p.L2470* STAT3 p.E616G TET2 p.K1254* TET2 p.C1289F SYNE1 c.4977-2delA VAV1 p.D797DV	1 6.55 18.51 17.36 20.88 29.85	n/a n/a n/a n/a n/a n/a		
27	Patient #28	AITL	IDH2 p.R172G JAK3 p.A746V TET2 p.R1216* TET2 p.C1273S TET2 p.H1817delinsTQfs	10.14 10.34 7.75 5.94 6.43	0 14.71 0 5.47 10.89		
28	Patient 29#	AITL	PLCG1 p.S520F RHOA p.G17VG TET2 p.L1111* TET2 p.C1211delinsLFfs DNMT3A p.R882H	12.52 10.86 11.82 12.37 46	0.19 0.1 0.56 0 35.6		

LN, lymph node
BM, bone marrow
PBL, peripheral blood
VAF, variant allele frequency
DLBCL, diffuse large B cell lymphoma
Vaf values highlighted in yellow represent those of the AITL mutations invovled in bone marrow
Vaf values highlighted in pink represent those of the mutations found only in bone marrow
[&] detected in DLBCL (renal tissue) by myeloid panel
n/a, no data available
PV, polycythemia vera
MF, myelofibrosis
TFH, follicular T helper cell
Alt%, alternate allele frequency
Alt% highlighted in yellow represent those of the AITL mutations invovled in bone marrow
Alt% highlighted in pink represent those of the mutations found only in bone marrow